Navigation Links
Osseon Receives CE Mark
Date:9/21/2009

SANTA ROSA, Calif., Sept. 21 /PRNewswire/ -- Osseon Therapeutics announced today that its Osseoflex (steerable and curvable bone cement delivery needle) and Osseoflex DR (steerable and curvable bone drill) systems for percutaneous vertebral augmentation received CE Mark approval for marketing and clinical use in the European Union.

CE Mark approval roughly corresponds to FDA approval in the United States, and allows for the Osseon systems to be used by surgeons and interventional radiologists for treatment of symptomatic vertebral fractures throughout Europe. Countries in numerous other regions including India, South America, and the Middle East also accept CE Mark approval as proof of clinical suitability, allowing for Osseon's steerable and curvable systems to be used in markets comprising nearly two billion people.

The Osseoflex systems employ a proprietary steerable access device to symptomatically correct acute fractures of the spinal vertebrae. These are seen in hundreds of thousands of patients annually, most commonly due to osteoporosis but also resulting from trauma or malignancy. The ability to access the entire vertebra through a single point of access reduces procedure time and decreases risk compared to systems requiring multiple points of access. This advantage, in turn, provides not only reliable clinical benefit, but reduces costs to hospitals, payors and ultimately patients. The Osseoflex systems, in conjunction with the proprietary Osseoperm biocompatible cement system have been in clinical use in the United States since December 2008. Data from nearly 400 patients at multiple centers in thirty states confirm the efficiency and efficacy of the Osseon system, with most patients treated as an outpatient with excellent pain relief.

"This is a great milestone for our company and our Osseoplasty System," said John Stalcup Ph.D., CEO of Osseon. "We knew that osseoplasty represented advancement for patient care, and we've seen it in the level of satisfaction from both physicians and patients. Now, we can bring that same advancement to a much broader market and patient population literally around the world."

Osseon website: http://www.osseon.com/

    Contact: Michael Bivens
             Marketing Director
             503-475-3333
             michael.bivens@osseon.com


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 2017 , ... Wash Tower Ltd. has released a series of six viral ... world's first standalone constant pressure bidet. , The videos in the series titled "The ... as well as on its social media pages. , Each video stars Arthur ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... An intensive ... could occasionally transmit HIV, reports Leslie Norins, MD, PhD. He says investigating ... of domestically transmitted Zika virus and in new infections with HIV. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... research collaboration to translate advances in basic neuroscience at the BMRI labs into ... collaboration seeks to improve movement, vision, and cognition impaired by stroke, traumatic brain ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... north Jersey and the New York metropolitan region, is embarking on a cooperative ... homeless families. , At present, more than two and a half million children ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... planning, and related services to communities across eastern Texas, is announcing a charity ... providing meals to hungry children and adults. , Consistently a top-rated nonprofit ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)...  ImaginAb Inc. today announced the appointment of Martyn Coombs ... , chairman of ImaginAb, said "At ImaginAb we have exciting science ... relevant to our business, particularly in commercializing and making step changes ... we can realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear ...
(Date:3/22/2017)... 2017 Research and Markets has announced ... Market & Clinical Pipeline Insight 2022" drug pipelines to ... ... Pipeline Insight 2022 report gives comprehensive insight on clinical and ... check point inhibitors as main streamline drugs in the immunotherapy ...
(Date:3/22/2017)... LINCOLN, Mass. , March 22, 2017 /PRNewswire/ ... applying mechanistic modeling to drug research and development, ... QSP Day 2017.  QSP Day 2017 is a ... with the quantitative systems pharmacology (QSP) community. The ... mathematical modeling is de-risking and accelerating drug research ...
Breaking Medicine Technology: